51
|
Nomura S. Identification, Friend or Foe: Vimentin and α-Smooth Muscle Actin in Cancer-Associated Fibroblasts. Ann Surg Oncol 2019; 26:4191-4192. [DOI: 10.1245/s10434-019-07894-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Indexed: 08/30/2023]
|
52
|
Kibata K, Izuno H, Nakahama K, Yamanaka Y, Kaneda T, Yoshioka H, Kurata T, Nomura S. Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
53
|
Nakamura Y, Okamoto W, Kato T, Hasegawa H, Kato K, Iwasa S, Esaki T, Komatsu Y, Masuishi T, Nishina T, Nomura S, Fukui M, Matsuda S, Sato A, Fujii S, Odegaard J, Olsen S, Yoshino T. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
54
|
Okamoto W, Nakamura Y, Shiozawa M, Komatsu Y, Denda T, Hara H, Kagawa Y, Narita Y, Kawakami H, Esaki T, Nishina T, Izawa N, Ando K, Moriwaki T, Kato T, Nagashima F, Satoh T, Nomura S, Yoshino T, Akagi K. Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.091] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
55
|
Kirita K, Sugiyama E, Togashi Y, Udagawa H, Irie T, Iida S, Nakamoto M, Nomura S, Ikeda T, Zenke Y, Matsumoto S, Yoh K, Niho S, Sato A, Nishikawa H, Goto K. Clinical utility of precision immunoprofiling and monitoring of the tumour microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: Results from a phase II study for biomarker analysis (EPOC1702). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
56
|
Zenke Y, Yoh K, Sakakibara-Konishi J, Daga H, Hosomi Y, Nogami N, Okamoto I, Matsumoto S, Kuroda S, Wakabayashi M, Nomura S, Ishii G, Sato A, Tsuboi M, Goto K. P1.18-04 Neoadjuvant Ceritinib for Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: SAKULA Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
57
|
Takahari D, Kawazoe A, Nakamura Y, Tamura H, Fukutani M, Hirano N, Wakabayashi M, Nomura S, Sato A, Shitara K. A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
58
|
Tanaka A, Ito T, Kibata K, Inagaki-Katashiba N, Amuro H, Nishizawa T, Son Y, Ozaki Y, Nomura S. Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus. Lupus 2019; 28:1120-1127. [PMID: 31299881 DOI: 10.1177/0961203319862865] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Sensing self-nucleic acids through toll-like receptors in plasmacytoid dendritic cells (pDCs), and the dysregulated type I IFN production, represent pathogenic events in the development of the autoimmune responses in systemic lupus erythematosus (SLE). Production of high-mobility group box-1 protein (HMGB1) promotes type I IFN response in pDCs. To better understand the active pathogenic mechanism of SLE, we measured serum levels of HMGB1, thrombomodulin, and cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-17F, IFNα, IFNγ, TNFα) in 35 patients with SLE. Serum HMGB1 and IFNα were significantly higher in patients with active SLE (SLE Disease Activity Index (SLEDAI) score ≥ 6) compared with healthy donors or patients with inactive SLE. Furthermore, the HMGB1 levels were significantly correlated with IFNα levels. By qualitative analysis, the detection of serum IFNα or HMGB1 suggests active SLE and the presence of SLE-related arthritis, fever, and urinary abnormality out of SLEDAI manifestations. Collectively, HMGB1 and IFNα levels are biomarkers reflecting disease activity, and qualitative analysis of IFNα or HMGB1 is a useful screening test to estimate SLE severity and manifestations. Our results suggest the clinical significance of type I IFNs and HMGB1 as key molecules promoting the autoimmune process in SLE.
Collapse
|
59
|
Hara H, Fukuoka S, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Sugama A, Wakabayashi M, Nomura S, Sato A, Togashi Y, Nishikawa H, Shitara K. Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz157.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
60
|
Rao M, Nomura S. TMS in treatment of Cocaine Use Disorder. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
61
|
Yang Q, Yasuda T, Choi E, Toyoda T, Roland JT, Uchida E, Yoshida H, Seto Y, Goldenring JR, Nomura S. MEK Inhibitor Reverses Metaplasia and Allows Re-Emergence of Normal Lineages in Helicobacter pylori-Infected Gerbils. Gastroenterology 2019; 156:577-581.e4. [PMID: 30391471 PMCID: PMC6368860 DOI: 10.1053/j.gastro.2018.10.049] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 09/23/2018] [Accepted: 10/23/2018] [Indexed: 12/19/2022]
|
62
|
Higashizono K, Nomura S, Yagi K, Aikou S, Nishida M, Yamashita H, Seto Y. Pregnancy, delivery, and breastfeeding after total gastrectomy for gastric cancer: a case report. World J Surg Oncol 2018; 16:229. [PMID: 30497494 PMCID: PMC6267826 DOI: 10.1186/s12957-018-1531-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Accepted: 11/21/2018] [Indexed: 12/12/2022] Open
Abstract
Background The reports of pregnancy after total gastrectomy for gastric cancer are rare. Case presentation We report a case of a 35-year-old woman, gravida 0, para 0, who became pregnant and delivered a baby 2 years and 6 months after laparoscopic-assisted total gastrectomy for early gastric cancer. Postoperatively, she showed a good progress during the follow-up and was continuously taking oral iron supplement and administered with methylcobalamin intramuscular injection. Two years after gastrectomy, she became pregnant. During the pregnancy, she kept taking iron and vitamin B12 supplementation and had a good course of pregnancy and a normal delivery. However, 2 months after the delivery, liver dysfunction was detected via blood examination. The patient switched from exclusive breastfeeding to combined feeding with formula, and her laboratory results returned to normal. During 10 years of follow-up after the delivery, the patient was in good condition without any recurrence and nutritional deficiencies, and her child had thrived. Conclusions Careful monitoring and management of iron and vitamin deficiencies are essential during pregnancy and the lactation periods for patients who previously underwent total gastrectomy. During the lactation period, a combination of formula and breastfeeding provides maternal and fetal nutritional support.
Collapse
|
63
|
Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Kuroda S, Nomura S, Sato A, Tsuchihara K, Kohno T, Matsumoto S, Goto K. LURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.108] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
64
|
Takahashi H, Morizane C, Nomura S, Okano N, Tsuda M, Mizuno N, Satake H, Tsuji K, Shioji K, Ishii H, Yasui K, Miyakawa H, Ishiguro A, Ogura T, Ueno M, Ikeda A, Terashima T, Ikeda M, Okusaka T, Furuse J. Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.114] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
65
|
Kato K, Kojima T, Saeki H, Hara H, Kajiwara T, Hironaka S, Nakatsumi H, Kadowaki S, Kagawa Y, Esaki T, Moriwaki T, Kobayashi T, Izawa N, Nomura S, Kuwata T, Fujii S, Okamoto W, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
66
|
Izawa N, Morizane C, Takahashi H, Ueno M, Kawamoto Y, Okano N, Shimizu S, Sudo K, Itoh S, Asagi A, Kagawa Y, Kamata K, Kudo T, Nomura S, Kuwata T, Fujii S, Okamoto W, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
67
|
Enokida T, Ogawa T, Homma A, Okami K, Minami S, Iwae S, Nakanome A, Shimizu Y, Motegi A, Maki D, Ueda Y, Fujisawa T, Nomura S, Okano S, Tahara M. A multicenter phase II trial of paclitaxel, carboplatin and cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
68
|
Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Sakamoto S, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T. BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
69
|
Kotani D, Bando H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Sakamoto S, Iida S, Matsuda S, Yonemura M, Fuse N, Sato A, Fujii S, Ebi H, Ohtsu A, Yoshino T. BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.152] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
70
|
Morizane C, Komatsu Y, Takahashi H, Ueno M, Furuse J, Kudo T, Itoh S, Shimizu S, Nakamura K, Kamata K, Ohtsubo K, Mizukami T, Kagawa Y, Nomura S, Kuwata T, Fujii S, Okamoto W, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
71
|
Leung C, Huang H, Saito E, Nomura S, Katanoda K, Matsuda T, Shibuya K. Benefits and Harms of Gastric Cancer Screening and Prevention in Japan: A Microsimulation Modeling Analysis. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.58700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: In 2016, gastric cancer is the second leading cause of cancer mortality worldwide. Globally, Japan and Korea are the only two countries implementing national screening program for gastric cancer. South Korea launched a biennial national -endoscopic screening program in 1999, which demonstrated a 47% reduction in gastric cancer mortality compared with no screening. In 2015, endoscopic screening was recommended by the Japanese Guideline for Gastric Cancer Screening. Currently, Japan's screening policy recommends endoscopic screening every 2 to 3 years for individuals aged 50 or above. Aim: This study aims to quantify the potential impacts of Japan's current national endoscopic screening policy and other alternative endoscopic screening options, and to identify a set of efficient endoscopic screening strategies for the current population of Japan. Methods: A microsimulation model of intestinal-type noncardia gastric adenocarcinoma was developed to simulate a virtual population with similar risk profile and life expectancy to the actual population of Japan. The model was calibrated and validated to the nationally-representative data from vital statistics and population-based cancer registries. The baseline scenario was modeled to project the current trend of gastric cancer. Variations among age of initiation (40, 45, 50, and 55), age of termination (75, 80, and 85), and screening interval (2, 5, 10, and 15 years) resulted in 39 unique endoscopic screening strategies for evaluation. In addition, the following three existing screening scenarios were included for analysis: the current screening program in Japan (screening every two or three years from age 50 years, with no termination) and Korea (biennial screening from age 40 years, with no termination). In total, 42 unique endoscopic screening strategies were simulated. Full adherence for all screening scenarios were assumed. Results: In comparison with baseline scenario, endoscopic screening strategies provided 43 to 203 life-years gained per 1000 individuals. The number of lifetime endoscopies per 1000 individuals ranged from 2281 to 28,635. The complications caused by screening were from 6 to 77 per 1000 individuals. The lifetime number of false-positive results ranged from 381 to 4941 per 1000 individuals. Scenarios simulating the current national endoscopic screening program in Japan and Korea fell below the efficient frontier. Under full adherence assumption, the most advantageous endoscopic screening strategy among evaluated scenarios is screening from age 40 to 80 years every 5 year. Conclusion: In this microsimulation modeling study with full adherence assumption, the findings suggest that the current national endoscopic screening program for gastric cancer in Japan might not be the most efficient screening option under benefit-to-harm consideration. The finding underpins the need for further investigation to bring up an efficient and cost-effective endoscopic screening program in Japan.
Collapse
|
72
|
Nomura S, Goldenring JR. Mind the Gap: Crossing Boundaries to Establish Reparative Metaplasia. Cell Mol Gastroenterol Hepatol 2018; 6:468-469. [PMID: 30364646 PMCID: PMC6198020 DOI: 10.1016/j.jcmgh.2018.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
|
73
|
Ko T, Nomura S, Fujita T, Satoh M, Fujita K, Harada M, Toko H, Aburatani H, Komuro I. 1429Single-cell analysis of non-cardiomyocytes in heart reveals a critical regulator of cardiac homeostasis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
74
|
Ueda T, Teagawa H, Fujii Y, Oshita C, Nomura S. P1551Brachial stiffness beta-value is associated with vascular thickness and cardiovascular risk factors. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
75
|
Satoh M, Nomura S, Fujita T, Ko T, Tobita T, Ito M, Fujita K, Aburatani H, Kobayashi Y, Komuro I. 4926High-throughput single-molecule RNA imaging analysis reveals spatial heterogeneity in heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.4926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|